Anthropic’s Claude AI Reportedly Used in U.S. Operation to Capture Nicolas Maduro 
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
Treasury Wine Estates Profit Falls 46% as China and U.S. Inventory Reset Weighs on Earnings 
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
Warner Bros. Discovery Weighs Renewed Sale Talks With Paramount Skydance Amid Netflix Deal Review 
(4) - EconoTimes)
SAN DIEGO, April 25, 2018 -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today reported grants under its Amended and Restated 2017 Inducement Equity Incentive Plan to two new employees who joined Vital Therapies.
The grants made April 24, 2018 are awards of nonstatutory stock options to purchase up to a total of 32,526 shares of Vital Therapies common stock. The options have an exercise price of $5.50, the closing price of Vital Therapies’ common stock on the grant date. The option grants will vest over four years with 1/48th of the total shares vesting monthly, subject to continued service. Each stock option has a ten-year term and is subject to the terms and conditions of the Amended and Restated 2017 Inducement Equity Incentive Plan and a stock option agreement covering the grant.
The grants were approved by the Vital Therapies Board of Directors on April 24, 2018. In accordance with NASDAQ Listing Rule 5635(c)(4), the grants were made as an inducement material to entering into an employment relationship with Vital Therapies.
About Vital Therapies, Inc.
Vital Therapies, Inc. is a biotherapeutic company developing a cell-based therapy targeting the treatment of acute forms of liver failure. The Company's ELAD System is an extracorporeal human allogeneic cellular liver therapy currently in phase 3 clinical trials. Vital Therapies, Inc. is based in San Diego, California. Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.
Contact:
Vital Therapies, Inc.
Al Kildani
Vice President, Investor Relations and Business Development
858-673-6840
[email protected]
